[S-28] Symposium 28 Novel therapeutic strategies against ischemic stroke from the perspective of neuro-glial-vascular unit

[S-28-3] The Effects of TrkB agonist for changing A1 to A2 astrocyte under prolonged cerebral hypoperfusion

^○Nobukazu Miyamoto¹, Shunsuke Magami², Kennichiro Hira¹, Toshiki Inaba¹, Yuji Ueno¹, Nobutaka Hattori¹ (1.Department of Neurology, Juntendo University school of medicine, Japan, 2.Department of Neurosurgery, Juntendo University school of medicine)

Dr. Nobukazu Miyamoto received his MD degree from Juntendo University in 2001. He received his PhD from Juntendo University in 2009 and was appointed Assistant Professor of Neurology at Juntendo University in the same year. In 2011-2013, he joined Neuroprotection Research Laboratory at Massachusetts General Hospital/Harvard Medical School as Research Fellow. He moved to Juntendo Urayasu hospital in 2013-2016, as Assistant Professor. Since he moved to the Neurology at Juntendo University (Prof Hattori N.) in 2017 as Associate Professor, his research interests have focused on oligodendrogenesis and cell-cell interaction between oligodendrocyte and other cells under chronic cerebral hypoperfusion in white matter, and neuroprotection of acute cerebral ischemia in basic science, and neurological deterioration of ischemic stroke in clinical research.